Related Experiment Videos

Ion conducting pores induced by oligo-L-alanine

F Heitz, G Spach, P Seta

Biochemical and Biophysical Research Communications

|July 30, 1982

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database.

Archives of gynecology and obstetrics·2022

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

Gynecologic oncology·2018

See all related articles